The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...
By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can ...
BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow ...
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan ...
Akero Therapeutics Inc (AKRO) stock saw a modest uptick, ending the day at $54 which represents a slight increase of $2.53 or 4.92% from the prior close of $51.47. The stock opened at $52.48 and ...
Zacks.com on MSN23h
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyAkero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic ...
Failed to fetch dynamically imported module: https://sg.finance.yahoo.com/assets/_app/immutable/nodes/100.sbqKNnJW.js ...
Jonathan Woo, an analyst from Phillip Securities, maintained the Buy rating on Akero Therapeutics (AKRO – Research Report). The associated ...
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback